Trial Profile

First-in-human clinical study of Typhoid conjugate vaccine

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Aug 2023 According to a Vaxxas media release, the global charitable foundation, Wellcome, has made an award totaling US$3.67 million (AU$5.4 million / GB2.84 million pound) to conduct IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine.
25 Aug 2023 New trial record
23 Aug 2023 According to a SK bioscience media release, SK bioscience and Vaxxas enter joint development agreement for needle-free patch delivery of typhoid vaccine in support with Wellcome. Vaxxas will be responsible for reformulating the SKYTyphoid antigen so that it can be applied to its proprietary HD-MAPs, and then conduct Phase I human clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com